AI Terminal
bioMérieux
Regulatory Filings • Dec 1, 2021
1152_iss_2021-12-01_4b073dad-bf47-4154-83b9-2780675b7213.pdf
Regulatory Filings
Open in ViewerOpens in native device viewer
bioMérieux molecular tests efficiently detect SARS-CoV-2 Omicron variant
As the incidence of infections with the SARS-CoV-2 Omicron variant (B.1.1. 529) continues to rise, there is much concern about diagnostic tests ability to efficiently detect this multi-mutated form of the COVID-19 virus.
Since the beginning of the pandemic bioMérieux's research and development teams have closely monitored the emergence of each variants of concern and systematically conducted in-depth in silico internal analyses.
These analyses allow us to confirm that to date our BIOFIRE® and ARGENE® molecular tests efficiently amplify and detect SARS-CoV-2 infection with Omicron variant with an unchanged performance.
From the early onset of the pandemic, bioMérieux has been committed to meet the COVID-19 public health challenge. We keep following the evolution of the pandemic and the scientific knowledge about the virus with the utmost attention and continuously work to anticipate developments in diagnostic tests that will meet future public health needs.
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2020, revenues reached €3.1 billion, with over 90% of international sales (outside of France).
bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agrifood, pharmaceutical and cosmetic products.
bioMérieux is listed on the Euronext Paris stock market. Symbol: BIM – ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg: BIM.FP Corporate website: www.biomerieux.com. Investor website:
CONTACTS Investor Relations bioMérieux Franck Admant Tel.: +33 (0)4 78 87 20 00 [email protected]
Media Relations
bioMérieux Image Sept [email protected] [email protected] [email protected]
Romain Duchez Laurence Heilbronn Claire Doligez Tel.: +33 (0)4 78 87 21 99 Tel.: +33 (0)1 53 70 74 64 Tel.: +33 (0)1 53 70 74 48